AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31050672 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7795
Study 29130976 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week ICT training intervention
Number of subjects: 19
Study 29130976 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study 29231298 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-hand-needling therapy (Sanjian (LI 3), Wailaogong (EX‐UE 8), Zhongzhu (TE 3), Houxi (SI 3) on the affected side)
Number of subjects: 80
Study 29231298 — intervention group
Group type: COMPARATOR
Intervention: Routine needling therapy at neck‐Jiaji (EX‐B 2) on bilateral C4, C5 and C6
Number of subjects: 80
Study 24096683 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG) 50 mg
Number of subjects: 16
Study 24096683 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CLcr >90 mL/min)
Number of subjects: 16
Study 22795636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate
Number of subjects: 171
Study 22795636 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone
Number of subjects: 171
Study 19744537 — intervention group
Group type: EXPERIMENTAL
Intervention: G1: hydrofluoric (HF) acid and silane
Number of subjects: 24
Study 19744537 — intervention group
Group type: COMPARATOR
Intervention: G2: silane alone
Number of subjects: 24
Study 19744537 — intervention group
Group type: EXPERIMENTAL
Intervention: G3: HF acid and silane then dried with warm air (100 degrees C)
Number of subjects: 24
Study 19744537 — intervention group
Group type: EXPERIMENTAL
Intervention: G4: silane alone then dried with warm air (100 degrees C)
Number of subjects: 24
Study 19020154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac 31.5 mg
Number of subjects: 127
Study 19020154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac 10 mg
Number of subjects: 127
Study 19020154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 17162326 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus acidophilus (La1) in yoghurt matrix, 1012 colony-forming units/subject/day for 42 days
Number of subjects: 0
Study 12798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Number of subjects: 66
Study 12798613 — intervention group
Group type: COMPARATOR
Intervention: Intradermal administration of anti-hepatitis B vaccine (20 microg, doses at 0, 15, and 30 days)
Number of subjects: 66
Study 11355929 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all‐trans retinoic acid (ATRA) and conventional anthracycline‐ARA‐C chemotherapy (CT)
Number of subjects: 0
Study 11355929 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged maintenance treatment with ATRA and low dose CT
Number of subjects: 0
Study 11355929 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid onset of CT and/or high dose steroids for ATRA syndrome
Number of subjects: 0
Study 11355929 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Number of subjects: 0
Study 11355929 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation CT using an anthracycline alone, without cytarabine
Number of subjects: 0
Study 11355929 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic or autologous stem cell transplantation after ATRA and CT
Number of subjects: 0
Study 9229600 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed Tip and Snip
Number of subjects: 30
Study 9229600 — intervention group
Group type: COMPARATOR
Intervention: Divide and Conquer
Number of subjects: 30
Study 7893774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample case with slight memory complaints
Number of subjects: 159
Study 7893774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample cases with moderate dementia (vascular dementia and degenerative dementia of Alzheimer type)
Number of subjects: 159
Study 7893774 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of treatable causes of dementia
Number of subjects: 159
Study 3107605 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 14
Study 3107605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30747758 — intervention group
Group type: EXPERIMENTAL
Intervention: ACES (Accelerated Chest pain Evaluation with Stress imaging)
Number of subjects: 334
Study 30747758 — intervention group
Group type: COMPARATOR
Intervention: Usual inpatient care
Number of subjects: 334
Study 28538556 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma (2 ml injected)
Number of subjects: 119
Study 28538556 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 119
Study 28538556 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvéderm Voluma
Number of subjects: 119
Study 25939517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at seven acupoints bilaterally
Number of subjects: 100
Study 25939517 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture points adjacent to the acupoints
Number of subjects: 100
Study 25939517 — intervention group
Group type: COMPARATOR
Intervention: Both acupuncture and sham groups
Number of subjects: 100
Study 24231251 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative telomere length (RTL) measured by quantitative PCR on blood or buccal cell DNA
Number of subjects: 299
Study 24231251 — intervention group
Group type: EXPERIMENTAL
Intervention: Short RTL (1st tertile) in males
Number of subjects: 299
Study 24231251 — intervention group
Group type: EXPERIMENTAL
Intervention: Short RTL (1st tertile) in females
Number of subjects: 299
Study 21989182 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil/folinic acid (FU/FA) treatment
Number of subjects: 211
Study 21989182 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 211
Study 19966605 — intervention group
Group type: EXPERIMENTAL
Intervention: Manometric biofeedback plus pelvic floor exercises
Number of subjects: 108
Study 19966605 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor exercises alone
Number of subjects: 108
Study 17076063 — intervention group
Group type: EXPERIMENTAL
Intervention: Synaesthesia prevalence testing using objective tests
Number of subjects: 0
Study 17076063 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapheme-colour synaesthesia
Number of subjects: 0
Study 17076063 — intervention group
Group type: EXPERIMENTAL
Intervention: Synaesthesia distribution across sexes
Number of subjects: 0
Study 15130230 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic radioisotope scintigraphy (DRS) using Tc99‐phytate labeled plain yogurt
Number of subjects: 40
Study 15130230 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of fluoroscopic image and barium swallow (FA)
Number of subjects: 40
Study 11777094 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential mixed frequency stimulation from a standard device
Number of subjects: 16
Study 11777094 — intervention group
Group type: EXPERIMENTAL
Intervention: New form of stimulation from an experimental stimulation device with simultaneous mixed frequency components
Number of subjects: 16
Study 11777094 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 16
Study 9008249 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed management strategy using home blood pressure monitoring
Number of subjects: 31
Study 9008249 — intervention group
Group type: COMPARATOR
Intervention: Office-based management through physician visits
Number of subjects: 31
Study 9008249 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-directed management
Number of subjects: 31
Study 9008249 — intervention group
Group type: COMPARATOR
Intervention: Office-based management
Number of subjects: 31
Study 8495604 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg EPA-E
Number of subjects: 24
Study 8495604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg EPA-E
Number of subjects: 24
Study 8495604 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1656 mg olive oil)
Number of subjects: 24
Study 30537847 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy instructions (n=19)
Number of subjects: 56
Study 30537847 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental constraints (n=17)
Number of subjects: 56
Study 30537847 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation (n=20)
Number of subjects: 56
Study 30388160 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg DNA-IIV3
Number of subjects: 75
Study 30388160 — intervention group
Group type: COMPARATOR
Intervention: IIV3-IIV3
Number of subjects: 75
Study 27650514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Chest Compressions (CCC)
Number of subjects: 63
Study 27650514 — intervention group
Group type: COMPARATOR
Intervention: 30:2 Chest Compressions to Ventilations
Number of subjects: 63
Study 24317366 — intervention group
Group type: EXPERIMENTAL
Intervention: E+R (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1))
Number of subjects: 18
Study 24317366 — intervention group
Group type: EXPERIMENTAL
Intervention: E+R+S (epigallocatechin-gallate 282 mg day(‐1) + resveratrol 200 mg day(‐1) + soy isoflavones 80 mg day(‐1))
Number of subjects: 18
Study 24317366 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 18
Study 22992814 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior route of injection
Number of subjects: 75
Study 22992814 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral route of injection
Number of subjects: 75
Study 22992814 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior route of injection
Number of subjects: 75
Study 22992814 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior route of injection in females
Number of subjects: 75
Study 22992814 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior route of injection in males
Number of subjects: 75
Study 20560909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 1000 μg
Number of subjects: 24
Study 20560909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone proprionate (FP) 1000 μg
Number of subjects: 24
Study 20560909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20560909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) and Fluticasone proprionate (FP)
Number of subjects: 24
Study 18633020 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative IV dexamethasone 8 mg and ondansetron 4 mg, followed by 8 mg oral disintegrating ondansetron tablet on discharge and in the morning of postoperative days 1 and 2.
Number of subjects: 60
Study 18633020 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative IV ondansetron 4 mg (control group).
Number of subjects: 60
Study 15863529 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patch (300 mug/d)
Number of subjects: 533
Study 15863529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study 11844962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients (CF)
Number of subjects: 54
Study 11844962 — intervention group
Group type: COMPARATOR
Intervention: Non-CF controls (healthy individuals and individuals with acute cold)
Number of subjects: 54
Study 9918281 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbomix
Number of subjects: 0
Study 9918281 — intervention group
Group type: COMPARATOR
Intervention: Actidose‐Aqua
Number of subjects: 0
Study 7570788 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment plus 1-semester experimental program
Number of subjects: 105
Study 7570788 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment plus 2-semester experimental program
Number of subjects: 105
Study 7570788 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only group
Number of subjects: 105
Study 2405109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 75 mg/m2 and doxorubicin (Dox) 50 mg/m2 intravenously every 3 weeks
Number of subjects: 28
Study 2405109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) and doxorubicin (Dox) as neoadjuvant therapy
Number of subjects: 28
Study 2405109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) and doxorubicin (Dox) as sole therapy
Number of subjects: 28
Study 2405109 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality therapy (CT followed by surgery or radiation therapy)
Number of subjects: 28
Study 7437258 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolintane (15 mg)
Number of subjects: 6
Study 7437258 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolintane (30 mg)
Number of subjects: 6
Study 7437258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (60 mg)
Number of subjects: 6
Study 7437258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemoline (100 mg)
Number of subjects: 6
Study 30388242 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental protein feeding (four commercially available protein supplements, wildflower pollen supplement)
Number of subjects: 75
Study 30388242 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no supplemental protein)
Number of subjects: 75
Study 30012122 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies including patient education booklet, online cancer pain education module, audit and feedback
Number of subjects: 492
Study 30012122 — intervention group
Group type: COMPARATOR
Intervention: Routine screening for average and worst pain using a 0-10 NRS and access to online guidelines
Number of subjects: 492
Study 28053985 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical-cognitive dual task (DT) training
Number of subjects: 36
Study 28053985 — intervention group
Group type: COMPARATOR
Intervention: Physical single task (ST) training
Number of subjects: 36
Study 28053985 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DT and ST)
Number of subjects: 36
Study 25281275 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control strategy (including electrical cardioversion and pharmacotherapy)
Number of subjects: 60
Study 25281275 — intervention group
Group type: COMPARATOR
Intervention: Rate control strategy
Number of subjects: 60
Study 22305837 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 1,000 U/kg intravenously immediately after reperfusion
Number of subjects: 110
Study 22305837 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care alone)
Number of subjects: 110
Study 20571180 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone co-administered with fluoxetine (ESZ+FLX)
Number of subjects: 434
Study 20571180 — intervention group
Group type: COMPARATOR
Intervention: Placebo co-administered with fluoxetine (PBO+FLX)
Number of subjects: 434
Study 17505681 — intervention group
Group type: EXPERIMENTAL
Intervention: 21-week exercise group (n = 10), low to moderate intensity, 60 minutes, 2 days/week
Number of subjects: 20
Study 17505681 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study 15763646 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy capsules
Number of subjects: 72
Study 15763646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11965273 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 592
Study 11965273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592
Study 9798453 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin nasal ointment
Number of subjects: 1044
Study 9798453 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 1044
Study 7674691 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention in heart failure
Number of subjects: 0
Study 2678162 — intervention group
Group type: EXPERIMENTAL
Intervention: VALERINA NATT (valerian preparation)
Number of subjects: 100
Study 2678162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 301629 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram of vitamin D2
Number of subjects: 21
Study 301629 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram of 25 hydroxyvitamin D3
Number of subjects: 21
Study 301629 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram of 5,6 trans‐25 hydroxyvitamin D3
Number of subjects: 21
Study 31849040 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory oxygen fraction of 0.80 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Number of subjects: 600
Study 31849040 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory oxygen fraction of 0.30 and intravenous bolus of vitamin C and infusion of N-acetylcysteine
Number of subjects: 600
Study 31849040 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory oxygen fraction of 0.80 and matching placebo
Number of subjects: 600
Study 31849040 — intervention group
Group type: COMPARATOR
Intervention: Inspiratory oxygen fraction of 0.30 and matching placebo
Number of subjects: 600
Study 31062459 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature
Number of subjects: 210
Study 28993130 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait retraining intervention (6-week program of increasing cadence and use of a minimalist shoe)
Number of subjects: 16
Study 28993130 — intervention group
Group type: COMPARATOR
Intervention: Foot orthoses (prefabricated)
Number of subjects: 16
Study 26705095 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional counseling
Number of subjects: 0
Study 26705095 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered counseling
Number of subjects: 0
Study 26705095 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered counseling with audio reinforcement
Number of subjects: 0
Study 24635002 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Psychoanalytic Child Therapy (PaCT), 20-25 sessions
Number of subjects: 30
Study 24635002 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term Psychoanalytic Child Therapy (PaCT)
Number of subjects: 30
Study 22158101 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 18
Study 20477768 — intervention group
Group type: EXPERIMENTAL
Intervention: Kessler's K6 psychological distress scale
Number of subjects: 71
Study 20477768 — intervention group
Group type: EXPERIMENTAL
Intervention: Kessler's K10 psychological distress scale
Number of subjects: 71
Study 20477768 — intervention group
Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 71
Study 20477768 — intervention group
Group type: COMPARATOR
Intervention: Hamilton Depression Rating Scale (HDRS)
Number of subjects: 71
Study 18083471 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg lornoxicam infusion 30 minutes before skin incision
Number of subjects: 44
Study 18083471 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion immediately after skin closure (control group)
Number of subjects: 44
Study 16128938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenatoprazole 40 mg once daily
Number of subjects: 30
Study 16128938 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 30
Study 14585672 — intervention group
Group type: EXPERIMENTAL
Intervention: New TBE vaccine
Number of subjects: 222
Study 14585672 — intervention group
Group type: COMPARATOR
Intervention: Formerly licensed TBE vaccine
Number of subjects: 222
Study 10554902 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose with IMI of 0 min
Number of subjects: 15
Study 10554902 — intervention group
Group type: COMPARATOR
Intervention: Placebo with IMI of 30 min
Number of subjects: 15
Study 9076651 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone formulation change
Number of subjects: 177
Study 1725029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 92
Study 1725029 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 92
Study 1725029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 6205336 — intervention group
Group type: EXPERIMENTAL
Intervention: salm-calcitonin and polychemo-therapy or hormonal treatment
Number of subjects: 48
Study 6205336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no calcitonin therapy)
Number of subjects: 48
Study 30694881 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk thistle (150 mg to 300 mg twice a day)
Number of subjects: 20
Study 30694881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30694881 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk thistle
Number of subjects: 20
Study 28343976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (25 Gy in ten daily fractions of 2·5 Gy)
Number of subjects: 224
Study 28343976 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 224
Study 28343976 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation
Number of subjects: 224
Study 26536022 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine (1-6 mg per dose, mean 3.4 mg) administered 3 times at 2-hour intervals
Number of subjects: 16
Study 26536022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23632348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-based Harvey Bradshaw Index (P-HBI)
Number of subjects: 181
Study 23632348 — intervention group
Group type: COMPARATOR
Intervention: Clinician-based Harvey Bradshaw Index (HBI)
Number of subjects: 181
Study 21233014 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel 75 mg/m², cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 4 days)
Number of subjects: 501
Study 21233014 — intervention group
Group type: COMPARATOR
Intervention: PF (cisplatin 100 mg/m², fluorouracil 1000 mg/m² for 5 days)
Number of subjects: 501
Study 21233014 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 501
Study 21233014 — intervention group
Group type: COMPARATOR
Intervention: PF
Number of subjects: 501
Study 19225296 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (specific type not mentioned)
Number of subjects: 0
Study 19225296 — intervention group
Group type: COMPARATOR
Intervention: Control (no statin therapy)
Number of subjects: 0